What's new — Migraine¶
Generated 2026-09-03 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 1 |
| last 2 months | 1 |
| last 3 months | 5 |
| last 6 months | 7 |
| last year | 14 |
| older than a year | 374 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-08-04 | Effectiveness of Onabotulinumtoxin-A in Patients with Chronic Migraine and Previous CGRP-mAb Treatment Failure: A Multicentre 6-Month Real-World Experience — Toxins (Basel) ([PMID 42646770](https://pubmed.ncbi.nlm.nih.gov/42646770/){target="_blank" rel="noopener"}) | preventive-treatment |
| 2026-07-02 | Lamotrigine prophylaxis is associated with reduced aura frequency in patients with burdensome migraine aura: a retrospective observational study — Front Neurol ([PMID 42591364](https://pubmed.ncbi.nlm.nih.gov/42591364/){target="_blank" rel="noopener"}) | aura-and-cortical-spreading-depolarization |
| 2026-07-02 | Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial — Lancet Neurol ([PMID 42492556](https://pubmed.ncbi.nlm.nih.gov/42492556/){target="_blank" rel="noopener"}) | clinical-trials-landscape, overview, preventive-treatment |
| 2026-07-02 | Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program — Cephalalgia ([PMID 42390441](https://pubmed.ncbi.nlm.nih.gov/42390441/){target="_blank" rel="noopener"}) | comorbidity-and-vascular-risk |
| 2026-07-01 | Migraine-advanced preventative treatments: the British Association for the Study of Headache Clinical Practice Recommendations and Consensus Guidance — J Neurol Neurosurg Psychiatry ([PMID 42469019](https://pubmed.ncbi.nlm.nih.gov/42469019/){target="_blank" rel="noopener"}) | guidelines |
| 2026-06-03 | The Social Life of Migraine: A Meta-Ethnography of Lived Experience in Adults With Migraine — Health Serv Insights ([PMID 42256516](https://pubmed.ncbi.nlm.nih.gov/42256516/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-04-01 | Sex-specific management of migraine a systematic review and consensus statement from the European Headache Federation (EHF) — J Headache Pain ([PMID 41998499](https://pubmed.ncbi.nlm.nih.gov/41998499/){target="_blank" rel="noopener"}) | guidelines, sex-hormones-pregnancy-and-lactation |
| 2026-03-02 | Redefining status migrainosus: A narrative review — Headache ([PMID 41902388](https://pubmed.ncbi.nlm.nih.gov/41902388/){target="_blank" rel="noopener"}) | classification-and-diagnosis |
| 2026-02-02 | Unmet treatment needs in migraine: Results of the OVERCOME (US) study — Headache ([PMID 41721442](https://pubmed.ncbi.nlm.nih.gov/41721442/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-02-02 | Dual-mechanism preventive therapy in chronic migraine: an exploratory meta-analysis of onabotulinumtoxinA and anti-CGRP monoclonal antibody combination — Eur J Med Res ([PMID 41721358](https://pubmed.ncbi.nlm.nih.gov/41721358/){target="_blank" rel="noopener"}) | chronic-migraine-and-chronification, preventive-treatment |
| 2025-12-09 | Evoked potential studies in migraine: A systematic review of neurophysiological patterns across migraine subtypes — Cephalalgia ([PMID 41364425](https://pubmed.ncbi.nlm.nih.gov/41364425/){target="_blank" rel="noopener"}) | biomarkers |
| 2025-12-01 | 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies — Headache ([PMID 41321235](https://pubmed.ncbi.nlm.nih.gov/41321235/){target="_blank" rel="noopener"}) | guidelines |
| 2025-12-01 | Global, regional, and national burden of headache disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 — Lancet Neurol ([PMID 41240916](https://pubmed.ncbi.nlm.nih.gov/41240916/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2025-10-02 | International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine — Cephalalgia ([PMID 41117312](https://pubmed.ncbi.nlm.nih.gov/41117312/){target="_blank" rel="noopener"}) | guidelines |
Trials — what has moved¶
40 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 2 |
| trial records updated in the last month | 8 |
| trial records updated in the last 2 months | 10 |
| trial records updated in the last 3 months | 11 |
| trial records updated in the last 6 months | 16 |
| trial records updated in the last year | 21 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-07-02 | Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess A | PHASE3 | 545 | Percentage of Participants Who Discontinued Treatment Due to Treatment | 18 | 404 | 0 |
| 2023-03-16 | Randomized Trial in Adult Participants With Acute Migraines | PHASE3 | 1978 | Percentage of Participants With Freedom From Pain at 2 Hours Post-dose | 0 | 160 | 0 |
| 2021-08-09 | Head-to-head Study of Erenumab Against Topiramate in Patients With Epi | PHASE4 | 777 | Proportion of Patients With Treatment Discontinuation Due to an Advers | 29 | 584 | 0 |
| 2021-08-09 | Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adu | PHASE2, PHASE3 | 1590 | Change From Baseline in the Mean Number of Total Migraine Days Per Mon | 24 | 153 | 2 |
| 2020-06-09 | Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migrai | PHASE3 | 1121 | Change From Baseline in Monthly Migraine Days | 10 | 128 | 0 |
| 2020-03-27 | Trial in Adult Subjects With Acute Migraines | PHASE3 | 1811 | Percentage of Participants With Freedom From Pain at 2 Hours Post-dose | 0 | 0 | 0 |
| 2019-01-29 | Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Tre | PHASE3 | 1686 | Percentage of Participants With Pain Freedom at 2 Hours After Initial | 1 | 0 | 0 |
| 2018-11-29 | Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the | PHASE3 | 862 | Overall Mean Change From Baseline in the Number of Monthly Migraine He | 21 | 310 | 0 |
| 2018-11-08 | Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for | PHASE3 | 875 | Change From Baseline in the Monthly Average Number of Migraine Days Du | 13 | 378 | 1 |
| 2018-07-10 | Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Mig | PHASE3 | 955 | Change From Baseline in Mean Monthly Migraine Days to the Last 3 Month | 51 | 306 | 0 |
28 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| preventive-treatment | 2026-08-04 | 3 | 29 |
| aura-and-cortical-spreading-depolarization | 2026-07-02 | 1 | 29 |
| clinical-trials-landscape | 2026-07-02 | 1 | 15 |
| comorbidity-and-vascular-risk | 2026-07-02 | 1 | 25 |
| overview | 2026-07-02 | 1 | 27 |
| guidelines | 2026-07-01 | 4 | 32 |
| patient-experience-and-advocacy | 2026-06-03 | 2 | 25 |
| sex-hormones-pregnancy-and-lactation | 2026-04-01 | 1 | 26 |
| classification-and-diagnosis | 2026-03-02 | 1 | 27 |
| chronic-migraine-and-chronification | 2026-02-02 | 1 | 26 |
| biomarkers | 2025-12-09 | 1 | 27 |
| epidemiology-and-burden | 2025-12-01 | 1 | 25 |
| migraine-in-children-and-adolescents | 2025-04-03 | 0 | 26 |
| red-flags-and-safety-concerns | 2025-04-02 | 0 | 26 |
| acute-treatment | 2024-09-01 | 0 | 25 |
| neuromodulation-and-behavioral-care | 2024-09-01 | 0 | 25 |
| trigeminovascular-biology-and-cgrp | 2024-06-01 | 0 | 28 |
| medication-overuse-headache | 2024-04-02 | 0 | 25 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.